Plain-English translation of NCT06617000 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage trial testing a new treatment called , which is a type of immune cell therapy designed to fight hepatitis B-related liver cancer. The study will examine whether this medication is safe and whether it helps shrink tumors in people whose cancer has not responded well to standard treatments. Researchers are looking for the right dose and side effect profile.
Standard cancer treatments don't work well enough for everyone with advanced hepatitis B-related liver cancer, and some people run out of options. This trial exists to see whether training immune cells to attack cancer cells could offer a new hope for patients who need additional treatment choices.
You will receive the immune cell medication through infusion visits at the study center. Before receiving the treatment, you will likely undergo chemotherapy to prepare your body, and then the medication will be given intravenously. You will have multiple follow-up visits to monitor your safety, side effects, and how well the treatment is working, with blood tests and imaging scans at regular intervals. The study involves close medical supervision since this is early-stage testing of a new therapy.
AI-generated summary from trial data · Jul 9, 2026 · Not medical advice
China